CLC number:
On-line Access: 2024-08-27
Received: 2023-10-17
Revision Accepted: 2024-05-08
Crosschecked: 2022-03-03
Cited: 0
Clicked: 960
Guohua Wu, Jianguo Wu, Zihan Li, Shengyu Shi, Di Wu, Xuanbo Wang, Han Xu, Hui Liu, Yixiao Huang, Rending Wang, Jia Shen, Zhihong Dong & Shuqi Wang. Development of digital organ‑on‑a‑chip to assess hepatotoxicity and extracellular vesicle‑based anti‑liver cancer immunotherapy[J]. Journal of Zhejiang University Science D, 2022, 5(3): 437-450.
@article{title="Development of digital organ‑on‑a‑chip to assess hepatotoxicity
and extracellular vesicle‑based anti‑liver cancer immunotherapy",
author="Guohua Wu, Jianguo Wu, Zihan Li, Shengyu Shi, Di Wu, Xuanbo Wang, Han Xu, Hui Liu, Yixiao Huang, Rending Wang, Jia Shen, Zhihong Dong & Shuqi Wang",
journal="Journal of Zhejiang University Science D",
volume="5",
number="3",
pages="437-450",
year="2022",
publisher="Zhejiang University Press & Springer",
doi="10.1007/s42242-022-00188-1"
}
%0 Journal Article
%T Development of digital organ‑on‑a‑chip to assess hepatotoxicity
and extracellular vesicle‑based anti‑liver cancer immunotherapy
%A Guohua Wu
%A Jianguo Wu
%A Zihan Li
%A Shengyu Shi
%A Di Wu
%A Xuanbo Wang
%A Han Xu
%A Hui Liu
%A Yixiao Huang
%A Rending Wang
%A Jia Shen
%A Zhihong Dong & Shuqi Wang
%J Journal of Zhejiang University SCIENCE D
%V 5
%N 3
%P 437-450
%@ 1869-1951
%D 2022
%I Zhejiang University Press & Springer
%DOI 10.1007/s42242-022-00188-1
TY - JOUR
T1 - Development of digital organ‑on‑a‑chip to assess hepatotoxicity
and extracellular vesicle‑based anti‑liver cancer immunotherapy
A1 - Guohua Wu
A1 - Jianguo Wu
A1 - Zihan Li
A1 - Shengyu Shi
A1 - Di Wu
A1 - Xuanbo Wang
A1 - Han Xu
A1 - Hui Liu
A1 - Yixiao Huang
A1 - Rending Wang
A1 - Jia Shen
A1 - Zhihong Dong & Shuqi Wang
J0 - Journal of Zhejiang University Science D
VL - 5
IS - 3
SP - 437
EP - 450
%@ 1869-1951
Y1 - 2022
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1007/s42242-022-00188-1
Abstract: organ-on-a-chip systems have been increasingly recognized as attractive platforms to assess toxicity and to develop new therapeutic agents. However, current organ-on-a-chip platforms are limited by a “single pot” design, which inevitably requires holistic analysis and limits parallel processing. Here, we developed a digital organ-on-a-chip by combining a microwell array with cellular microspheres, which significantly increased the parallelism over traditional organ-on-a-chip for drug development. Up to 127 uniform liver cancer microspheres in this digital organ-on-a-chip format served as individual analytical units, allowing for analysis with high consistency and quick response. Our platform displayed evident anti-cancer efficacy at a concentration of 10 μM for sorafenib, and had greater alignment than the “single pot” organ-on-a-chip with a previous in vivo study. In addition, this digital organ-on-a-chip demonstrated the treatment efficacy of natural killer cell-derived extracellular vesicles for liver cancer at 50 μg/mL. The successful development of this digital organ-on-a-chip platform provides high-parallelism and a low-variability analytical tool for toxicity assessment and the exploration of new anticancer modalities, thereby accelerating the joint endeavor to combat cancer.
Open peer comments: Debate/Discuss/Question/Opinion
<1>